Johnson & Johnson JNJ announced that the FDA has accepted its regulatory filing seeking the FDA’s approval for nipocalimab, ...

5,6 Several studies have shown that FcRn-deficient mice are resistant to autoimmune disorders, particularly those with excessive serum concentrations of pathogenic IgG autoantibodies. The basis ...

This FcRn inhibitor is built on blocking the maintaining function of harmful IgG autoantibodies in circulation, which cause a severe immune response in this and other autoimmune disorders.

gMG is an autoantibody-driven neuromuscular disease marked by fluctuating muscle weakness. Nipocalimab has been designed to block FcRn and reduce levels of autoantibodies while preserving immune ...

Anti-FcRn antibody therapeutics reduce IgG levels ... been selected as its clinical candidate for chronic IgG-driven autoimmune diseases.

About Immunovant, Inc. Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the ...

The application is supported by data from the randomized, double-blind, placebo-controlled phase 3 Vivacity-MG3 study.